The authors say that their results provide encouraging data, indicating that in breast cancer survivors without a pre-existing cardiac history, the addition of trastuzumab to adjuvant anthracycline-based chemotherapy does not result in long-term worsening of cardiac function, cardiac symptoms, or health-related quality-of-life.